ArticleAmerican journal of physiology. Regulatory, integrative and comparative physiology2011
Neuronostatin acts in brain to biphasically increase mean arterial pressure through sympatho-activation followed by vasopressin secretion: the role of melanocortin receptors.
Article in American journal of physiology. Regulatory, integrative and comparative physiology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 35 citations in OpenAlex.
- An Angiotensin-Responsive Connection from the Lamina Terminalis to the Paraventricular Nucleus of the Hypothalamus Evokes Vasopressin Secretion to Increase Blood Pressure in Mice.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2021Article
- Glutamatergic Activation of Neuronostatin Neurons in the Periventricular Nucleus of the Hypothalamus.Brain sciences · 2020Article
- Expression and function of nesfatin-1 are altered by stage of the estrous cycle.American journal of physiology. Regulatory, integrative and comparative physiology · 2019Article
- Obesity, kidney dysfunction and hypertension: mechanistic links.Nature reviews. Nephrology · 2019Review
- Novel regulator of vasopressin secretion: phoenixin.American journal of physiology. Regulatory, integrative and comparative physiology · 2018Article
- P2X7 receptor regulates sympathoexcitatory response in myocardial infarction rats via NF-κB and MAPK pathways.American journal of translational research · 2017Article
- Hypoglycemia unawareness prevention: Targeting glucagon production.Physiology & behavior · 2016Review
- Association between a polymorphic poly-T repeat sequence in the promoter of the somatostatin gene and hypertension.Hypertension research : official journal of the Japanese Society of Hypertension · 2016Article
- Understanding peptide biology: The discovery and characterization of the novel hormone, neuronostatin.Peptides · 2015Review
- Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms.Circulation research · 2015Review
- Neuronostatin inhibits glucose-stimulated insulin secretion via direct action on the pancreatic α-cell.American journal of physiology. Endocrinology and metabolism · 2014Article
- The brain melanocortin system, sympathetic control, and obesity hypertension.Physiology (Bethesda, Md.) · 2014Review
- Role of leptin and central nervous system melanocortins in obesity hypertension.Current opinion in nephrology and hypertension · 2013Review
- Evidence for an interaction of neuronostatin with the orphan G protein-coupled receptor, GPR107.American journal of physiology. Regulatory, integrative and comparative physiology · 2012Article
- Pressor doses of vasopressin result in only transient elevations in plasma peptide levels.Peptides · 2012Article
- Somatostatinergic systems: an update on brain functions in normal and pathological aging.Frontiers in endocrinology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Neuronostatin is a recently described neuropeptide that is derived from the somatostatin preprohormone. We have shown previously that neuronostatin led to a biphasic, dose-related increase in mean arterial pressure when injected into the lateral cerebroventricle of adult, male rats. Because neuronostatin depolarized both magnocellular and parvocellular, paraventricular nucleus neurons in hypothalamic slice preparations, we hypothesized that neuronostatin elevated mean arterial pressure first by stimulating sympathetic nervous system activity followed by the release of a pressor hormone, specifically vasopressin. We found that the first phase of neuronostatin-induced increase in mean arterial pressure was reversed by pretreatment with phentolamine, indicating that phase 1 was, indeed, due to an increase in sympathetic activity. We also found that centrally injected neuronostatin led to a dose-related increase in vasopressin secretion in a time course consistent with the peak of the second phase. Furthermore, the second phase of arterial pressure elevation was reversed by pretreatment with a vasopressin 1 receptor antagonist, indicating that phase 2 was likely due to an increase in vasopressin secretion. We previously have shown that the anorexigenic and antidipsogenic effects of neuronostatin were reversed by pretreatment with the melanocortin 3/4 receptor antagonist, SHU9119, so we evaluated the ability of SHU9119 to reverse the effects of neuronostatin on MAP and vasopressin secretion. We found that SHU9119 abrogated the second phase of neuronostatin-induced increase in MAP and neuronostatin-induced vasopressin secretion, indicating that neuronostatin acts through the central melanocortin system to increase vasopressin release, ultimately leading to an elevation in MAP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.